New psilocybin data highlights challenges for anorexia drug development
New preclinical research shows that psilocybin’s behavioural and inflammatory effects…
New preclinical research shows that psilocybin’s behavioural and inflammatory effects vary with metabolic state and exercise, highlighting key biological variables that could inform drug discovery, target selection and patient stratification in psychedelic therapeutics.




